DEVELOPMENT OF HPLC STABILITY DEMONSTRATING METHODOLOGY FOR QUANTIFYING AZELNIDIPINE AND TELMISARTAN IN TABLETS AND BULK TYPES: VALIDATION FOLLOWING ICH DIRECTIVES

KRISHNAPHANISRI PONNEKANTI; K. SUNITHA

doi:10.22159/ijap.2021v13i5.42099

Authors

KRISHNAPHANISRI PONNEKANTI Department of Pharmacy, GITAM Institute of Pharmacy, GITAM Deemed to be University, Visakhapatnam, India 530045
K. SUNITHA Department of Pharmacy, GITAM Institute of Pharmacy, GITAM Deemed to be University, Visakhapatnam, India 530045

DOI:

https://doi.org/10.22159/ijap.2021v13i5.42099

Keywords:

Azelnidipine, Telmisartan, Hypertension, Stability demonstrating, Analysis

Abstract

Objective: Azelnidipine (AZEL) and Telmisartan (TELM) combination is referred to the sufferers of hypertension. No analytical process has yet been mentioned for the TELM and AZEL combination analysis. We, therefore, have designed for its first time stability demonstrating methodology based on HPLC for analysing TELM and AZEL in the tablets and bulk.

Methods: The assay of TELM and AZEL was get done on a 250 mm length C18 column (Supelco, 4.6 mm inner diameter, 5.0 μm particle size), and utilized 0.1M Na₂SO₄(pH 3.6) and acetonitrile (55% volume: 45% volume) as the mobile solvents phase, at a stream rate 1.0 ml/min. HPLC recognition of TELM and AZEL was taken by a photodiode array sensor set at 258 nm. For validation of the stability demonstrating methodology proposed in terms of sensitivity, precision, specificity, linearity, device adequacy, robustness and accuracy, ICH directives were followed.

Results: Calibration curves of TELM and AZEL were generated in the array of 20-60 µg/ml and 4-12 µg/ml with recovery percentage ranges of 99.62%-101.05% and 97.76%-100.17%, and detection limits of 0.020 µg/ml and 0.009 µg/ml, respectively. TELM and AZEL stability was inspected in the existence of acid, base, light, heat, and oxidation and it was realised to be more stable under oxidation degradation testing conditions employed when compared to acid, alkaline, photo, and heat degradation testing conditions applied.

Conclusion: The observations demonstrated that the described HPLC stability demonstrating methodology was suitable for quantitating TELM and AZEL combination in tablets and bulk.

Downloads

Download data is not yet available.

References

1. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PK. Hypertension. Nat Rev Dis Primers, 2018;4:18014.
2. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol, 2020;16:223-37.
3. Chen B, Zhang Y, Luo J, Zhang W. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Ther Clin Risk Manag, 2015;11:309-18.
4. Zhao X, Wu F, Jia S, Qu P, Li H, Zhao X, Cao B, Lin Y, Wang M. Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients. Clin Exp Hypertens, 2010;32:372-6.
5. Masaki W, Teruyuki H, Sadahisa O, Shinya S, Seiji T, Makoto U. Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study. Hypertens Res, 2010;33:43–8.
6. Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, Galli E. Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother, 2011;12:2719-35.
7. Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag, 2010; 6:113-33.
8. Ayza MA, Zewdie KA, Tesfaye BA, Gebrekirstos ST, Berhe DF. Anti-diabetic effect of telmisartan through its partial PPAR?-agonistic activity. Diabetes Metab Syndr Obes, 2020;13:3627-35.
9. Balakumar P, Bishnoi HK, Mahadevan N. Telmisartan in the management of diabetic nephropathy: a contemporary view. Curr Diabetes Rev, 2012;8:183-90.
10. Telmisartan + Azelnidipine. www.1mg.com, accessed on May 2021, Available at: https://www.1mg.com/generics/telmisartan-azelnidipine-509412
11. ICH Expert Working Group. International Conference on Harmonization (ICH) of technical requirements for the registration of pharmaceutical for human use stability testing of new drugs substance and products Q1A (R2) (2003).
12. Goparaju G, Kaushal G. Significance of Stability-Indicating LC Methods in Pharmaceuticals. Austin Chromatogr. 2014;1(1): 1-2.
13. ICH Expert Working Group. Validation of Analytical Procedures: Text and Methodology Q2 (R1); 2005.
14. Azim Md Sabir, Mitra Moloy, Parminder S Bhasin. HPLC method development and validation: A review. Int Res J Pharm, 2015;4:39-46.
15. Marcello L, Dora M, Giuseppe C, Clinio L. Recent HPLC strategies to improve sensitivity and selectivity for the analysis of complex matrices. Instrum Sci Technol, 2012;40, 112-37.
16. Panchumarthy R, Navya ChN, Pravallika D, Sri DN. A review on step-by-step analytical method validation. IOSR J Pharm, 2015;5:7-19.
17. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev, 2008;29 (Suppl 1):S49-S52.
18. Betz JM, Brown PN, Roman MC. Accuracy, precision, and reliability of chemical measurements in natural products research. Fitoterapia, 2011;82(1):44-52.
19. Zenkevich IG, Klimova IO. Use of the standard addition method in quantitative chromatographic analysis. J Anal Chem, 2006;61:967–72.
20. Sergio LCF, Adriana OC, Thaise da SB, Ariana MDSL, Laiana OBS, Walter NLS. Robustness evaluation in analytical methods optimized using experimental designs. Microchem J, 2017;131:163-9.
21. Shah BP, Jain S, Prajapati KK and Mansuri NY: Stability Indicating HPLC method development: A review. Int J Pharm Res Sci, 2012;3:2978-88.